TEL AVIV, Israel, May 17, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and ...

AMPLIFY-7P did not meet the pre-specified primary endpoint of disease-free survival (“DFS”) in the intent-to-treat population.Randomization ...

Novo Nordisk’s Ibrahim Kamstrup-Akkaoui outlines how the Danish GLP-1 giant is embedding AI into its clinical foundation.

New high-value indication for Phase 3-ready asset with data intended to support clinical development and strategic partnering ...

When healthtech and medtech companies fail, it's often not because their innovation lacks merit. It's due to foundational ...

QuantHealth, the leader in AI-powered clinical trial simulation, today announced the appointment of four executives from the world’s top pharmaceutical and AI organizations to its executive team. The ...

Former ImCheck Therapeutics clinical leader joins HEPHAISTOS-Pharma as the company prepares to advance its lead innate immunotherapy candidate into first-in-human studies Paris, France - May 19, 2026 ...

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced the appointment of two technology and clinical development leaders to senior roles to significantly strengthen the ...

Clearance enables Phase 2 evaluation of NEO212, the Company’s oral perillyl alcohol-temozolomide conjugate, in the United ...

Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsight The glioblastoma clinical trial analysis report delivers important insights into ...

IND enabling studies with CLD-401 to continue with IND submission targeted by end of 2026 as Calidi continues to explore regulatory filing for CLD-401 in Australia in parallel ...

Discusses Clinical Data and Updated Development Strategy for Darlifarnib June 3, 2026 3:15 PM EDTCompany ParticipantsTroy ...